Wayne State scientists are developing artificial intelligence models to cut costs in complex drug design, while Stanford research reveals ChatGPT-4 achieving 92% medical diagnostic accuracy — outperforming human doctors scoring 74%. This wave of AI breakthroughs is reflected in financial markets, where health tech stocks rose 12% in 2024 and AI healthcare companies now command valuations up to five times higher than their non-AI counterparts, attracting 38% of venture capital healthcare investments.
AI Models Could Cut Drug Development Costs
A project at Wayne State University aims to harness AI and computer models to design new medications, mainly focusing on complex drug types that have traditionally been difficult to simulate.
“Most drug design is done with small organic molecules,” Alice Walker, assistant professor of chemistry at Wayne State, said in a Monday (Oct. 28) news release. “The computation models we have to do this are good, but they have trouble with unusual drug scaffolds like sugars and florescent molecules. Our lab is going to use this grant to develop new computational techniques and apply them to the development of new carbohydrate drugs and fluorescent imaging agents.”
The study, funded by the National Institutes of Health, could lead to breakthrough treatments with fewer side effects. Walker’s team will combine simulations with machine learning to better understand molecular behavior, particularly in developing anti-cancer drug targets.
AI Outperforms Doctors in Medical Diagnosis Study
A new Stanford University study reveals that ChatGPT-4 achieved high diagnostic accuracy, scoring 92% when analyzing real patient cases — significantly outperforming traditional and AI-assisted physicians, who scored 74% and 76%, respectively.
Doctors with access to ChatGPT didn’t show significant improvement in their diagnostic reasoning compared to those without AI assistance, though they completed their assessments slightly faster. The findings suggest that medical professionals may need better training to leverage AI tools effectively in clinical settings.
“Our study shows that ChatGPT has potential as a powerful tool in medical diagnostics, so we were surprised to see its availability to physicians did not significantly improve clinical reasoning,” study co-lead author Ethan Goh, a postdoctoral scholar at Stanford’s School of Medicine, said in a blog post.
The research, published in JAMA Network Open, emphasizes that AI won’t replace doctors but could enhance their capabilities. In response to these findings, several major medical institutions have launched ARiSE, a bi-coastal network dedicated to evaluating AI applications in healthcare. The study highlights the need for improved physician-AI collaboration and proper integration of AI tools in clinical practice.
Health Tech Sector Rebounds
Health tech stocks rose 12% in 2024 while private market valuations returned to peak levels, driven largely by artificial intelligence investments, according to Bessemer Venture Partners’ annual industry report. The sector’s total public market capitalization now stands at $98 billion across 34 companies, including Tempus and Waystar, which both went public with initial public offerings (IPOs) earlier this yeart.
Bessemer partners Sofia Guerra and Steve Kraus wrote in their State of Health Tech 2024 report that the sector “has shown remarkable adaptability and strength in the face of ongoing market challenges.”
AI-focused companies are now attracting 38% of venture capital healthcare dollars, commanding valuations two to five times higher than their non-AI counterparts. However, challenges remain in early-stage funding, with Series A companies taking 50% longer to raise capital compared to previous years.
link